无功能垂体腺瘤的早期与延迟分次立体定向放疗比较
该单中心回顾性研究纳入2004年1月至2022年12月接受分次立体定向放疗(FSRT)的无功能垂体腺瘤(NFPA)患者75例,中位随访53个月,比较辅助治疗(ADJ)与进展后治疗(PRG)的内分泌、眼科和影像学结局。ADJ组与PRG组肿瘤控制率分别为94.3%和95.0%,新发内分泌病分别为4例(11.4%)和7例(17.5%),新发视野缺损分别为2例(5.7%)和1例(2.5%);至新发内分泌病时间在两组间无差异,但ADJ组从手术至新发内分泌病的中位时间显著短于PRG组(15.5个月 vs 102.0个月)。作者认为延迟治疗可推迟新发内分泌病的发生,并保持相似的肿瘤控制效果。
要点
- ADJ组与PRG组肿瘤控制率分别为94.3%和95.0%。
- ADJ组与PRG组新发内分泌病分别为4例(11.4%)和7例(17.5%)。
- ADJ组与PRG组从手术至新发内分泌病中位时间分别为15.5个月和102.0个月,差异显著。
核心结论
- FSRT对残留和进展性NFPA有效,肿瘤控制率优良,新发内分泌病和视野缺损风险低。
- 延迟治疗推迟了新发内分泌病的发生,提示对肿瘤进展者观察并行FSRT可能推迟垂体功能减退的发生,并保持相似的肿瘤控制效果。
研究设计与样本
- 单中心回顾性研究,纳入2004年1月至2022年12月接受FSRT的NFPA患者75例,中位随访53个月。
- FSRT作为辅助治疗(ADJ)35例,作为进展后治疗(PRG)40例,中位至治疗时间分别为5.5个月和40个月。
主要发现
- 肿瘤控制率ADJ组为94.3%,PRG组为95.0%。
- 新发内分泌病ADJ组4例(11.4%),PRG组7例(17.5%)。
- 新发视野缺损ADJ组2例(5.7%),PRG组1例(2.5%)。
- 至新发内分泌病时间的生存分析显示两组间无差异。
- 从手术至新发内分泌病的中位时间ADJ组为15.5个月,PRG组为102.0个月,差异显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fractionated stereotactic radiotherapy (FSRT) is a common modality used to treat pituitary adenomas with good control rates. It is not known whether FSRT should be performed early or delayed until progression occurs. We compared FSRT in treating nonfunctional pituitary adenomas (NFPA) as an adjuvant (ADJ) or on-progression (PRG) therapy. METHODS: A retrospective review of patients who underwent FSRT for an NFPA between January 2004 and December 2022 at a single institution was performed. We compared endocrinologic, ophthalmologic, and radiographic outcomes in FSRT delivered as ADJ and PRG treatment. RESULTS: Seventy-five patients were analyzed, with a median follow-up of 53 months. FSRT was administered to 35 and 40 patients as ADJ and PRG, with a median time to treatment of 5.5 and 40 months, respectively. The tumor control rate was 94.3% for ADJ and 95.0% for PRG. Treatment resulted in 4 (11.4%) versus 7 (17.5%) new endocrinopathies and 2 (5.7%) versus 1 (2.5%) new visual deficits for ADJ versus PRG. A survival analysis of time to new endocrinopathy showed no difference between the 2 cohorts. The median time from surgery to new endocrinopathy was significantly different between ADJ and PRG, at 15.5 and 102.0 months, respectively. CONCLUSIONS: FSRT is effective in treating NFPA for residual and progressive tumors, with excellent tumor control rates and a low risk of developing new endocrinopathies and visual deficits. Delaying treatment delayed the development of new endocrinopathies, suggesting that observation with FSRT on tumor progression may delay the onset of hypopituitarism and maintain similar effectiveness in tumor control.
引用
- Sathe AV, Siu A, Kang KC, et al. Early Versus Delayed Fractionated Stereotactic Radiotherapy for Nonfunctioning Pituitary Adenoma. World Neurosurg. 2023. PMID: 37757941. doi:10.1016/j.wneu.2023.09.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。